Skip to main content

Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.

Danila DC, Anand A, Schultz N, Heller G, Wan M, Sung CC, Dai C, Khanin R, Fleisher M, Lilja H, Scher HI

Publication: Eur Urol (2014) • Vol 65 • Page 1191-7PMID: 23954088View on PubMed

Purpose

This paper sought to determine whether levels of specific transcripts in peripheral blood are related to the number of circulating tumor cells (CTCs) determined using the CellSearch System.

Conclusion

At least two of the five genes targeted were detected by real-time RT-PCR in 53% of metastatic prostate cancer patients. CellSearch detected ≥5 CTCs/7.5ml blood (associated with poor prognosis) in 46% of metastatic prostate patients and 89% of those individuals also had detectable levels of two or more cancer-related genes by real-time RT-PCR assay. Importantly, 21% of patients with ≤4 CTCs/7.5 of blood (associated with a favorable prognosis) were also positive for two or more of the genes targeted by real-time RT-PCR.

Studies (1)

Purpose

This study sought to determine whether levels of specific transcripts in peripheral blood are correlated to the number of circulating tumor cells (CTCs) determined using the CellSearch System, and whether transcript detection alone or in combination with CTC count is predicative of prostate cancer patient prognosis. Peripheral blood was collected from 97 men with metastatic castration-resistant prostate cancer and 51 healthy volunteers in CellSave tubes and PAXgene tubes. Blood (7.5 mL/individual) collected in CellSave tubes was processed for CTC enumeration using the CellSearch system. Blood (2.5 mL) collected in PAXgene tubes were stored at -80°C until analysis by real-time RT-PCR for five prostate cancer-related genes (KLK3, KLK2, HOXB13, GRHL2, and FOXA1) for specimens that had an RNA intergrity number (RIN) that was ≥6. Intra-assay coefficient variability was performed in triplicate using six replicates and inter-assay variability was assessed in triplicate by three different technologists.

Summary of Findings

At least two of the five genes targeted were detected by real-time RT-PCR in 53% of patients diagnosed with metastatic prostate cancer (51/97). Five or more CTCs per 7.5 ml of blood were detected by CellSearch in 46% of metastatic prostate patients (45/97) and 89% (40/45) of those patients also had detectable levels of two or more genes targeted by real-time RT-PCR. Of the 45 patients with ≥5 CTCs/7.5ml blood (associated with poor prognosis), KLK3 alone was detected in two patients and FOXA1 alone was detected in one patient. None of the 5 transcripts were detected for one patient with 26 CTCs/7.5ml and a serum PSA <0.05ng/ml. Importantly, 21% (11 patients) of the 52 patients with ≤4 CTCs/7.5 of blood (associated with a favorable prognosis) had detectable levels of two or more of the five genes targeted by real-time RT-PCR. For the real-time RT-PCR assay, intra- and inter-assay variability were below the acceptable threshold (CV< 15%) for all five targeted genes (CV range of .27–2.98%, P<.0001 for all).

  • Biospecimens

    FluidBlood
  • Preservation Types

    Other PreservativePAXgene
  • Diagnoses

    NeoplasticCarcinoma
    Normal
  • Platforms

    Cell count/volumeFluorescent microscopy
    RNAReal-time qRT-PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen Aliquots and ComponentsCell capture method
    CellSearch System for CTC Enumeration
    Real-time qRT-PCR SpecificTargeted nucleic acid
    FOXA1
    GRHL2
    HOXB13
    KLK2
    KLK3